Treatment algorithm and prognostic factors for patients with stage I-III carcinoma of the anal canal: a 20-year multicenter study
Diane Bruyere,Franck Monnien,Prudence Colpart,Patrick Roncarati,Lucine Vuitton,Elodie Hendrick,Alexis Lepinoy,Alexandra Luquain,Charlotte Pilard,Thomas Lerho,Chloé Molimard,Philippe Maingon,Laurent Arnould,Marie-Christine Bone-Lepinoy,Laurence Dusserre,Laurent Martin,Celia Reynders,Marie Ancion,Didier Peiffert,Agnès Leroux,Pascale Hubert,Jean-Baptiste Delhorme,Jean-Pierre Ghnassia,Anne-Sophie Woronoff,Philippe Delvenne,Jean-Luc Prétet,Jean-François Bosset,Olivier Peulen,Christiane Mougin,Séverine Valmary-Degano,Michael Herfs
DOI: https://doi.org/10.1038/s41379-020-0637-6
Abstract:Despite a growing incidence in developed countries and a recent improved understanding of its pathogenesis, anal cancer management has not evolved over the past decades and drug combination used as first-line regimen still largely depends on clinician preferences. Aiming at paving the way for precision medicine, a large cohort of 372 HIV-negative patients diagnosed over a 20-year time period with locally advanced anal carcinoma was collected and carefully characterized at the clinical, demographic, histopathologic, immunologic, and virologic levels. Both the prognostic relevance of each clinicopathological parameter and the efficacy of different concurrent chemoradiation strategies were determined. Overall, the incidence of anal cancer peaked during the sixth decade (mean: 63.4) and females outnumbered males (ratio: 2.51). After completion of treatment, 95 (25.5%) patients experienced progression of persistent disease or local/distant recurrence and 102 (27.4%) died during the follow-up period (median: 53.8 months). Importantly, uni-multivariate analyses indicated that both negative HPV/p16ink4a status and aberrant p53 expression were far better predictors for reduced progression-free survival than traditional risk factors such as tumor size and nodal status. As for overall survival, the significant influences of age at diagnosis, p16ink4a status, cTNM classification as well as both CD3+ and CD4+ T-cell infiltrations within tumor microenvironment were highlighted. Cisplatin-based chemoradiotherapy was superior to both radiotherapy alone and other concurrent chemoradiation therapies in the treatment of HPV-positive tumors. Regarding their HPV-uninfected counterparts, frequent relapses were observed, whatever the treatment regimen administered. Taken together, our findings reveal that current anal cancer management and treatment have reached their limits. A dualistic classification according to HPV/p53 status should be considered with implications for therapy personalization and optimization.